Compare · ABT vs NBP
ABT vs NBP
Side-by-side comparison of Abbott Laboratories (ABT) and NovaBridge Biosciences (NBP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and NBP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 1217.0x NBP ($148.8M).
- ABT has been more active in the news (13 items in the past 4 weeks vs 5 for NBP).
- ABT has more recent analyst coverage (25 ratings vs 1 for NBP).
- Company
- Abbott Laboratories
- NovaBridge Biosciences
- Price
- -
- -
- Market cap
- $181.14B
- $148.8M
- 1M return
- +2.58%
- -
- 1Y return
- -18.39%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 13
- 5
- Recent ratings
- 25
- 1
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest NBP
- SEC Form 6-K filed by NovaBridge Biosciences
- Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
- Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
- NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
- Chief Medical Officer Dennis Phillip Andrew converted options into 23,695 units of Ordinary Shares and sold $5,828 worth of Ordinary Shares (8,209 units at $0.71), increasing direct ownership by 10% to 173,427 units (SEC Form 4)
- Chief Bus. Development Officer Cao Sean Wuxiong sold $79,904 worth of Ordinary Shares (107,978 units at $0.74), decreasing direct ownership by 29% to 266,467 units (SEC Form 4) (for tax liability)
- SEC Form 3 filed by new insider Dewhurst Martin William
- Chief Bus. Development Officer Cao Sean Wuxiong converted options into 339,372 units of Ordinary Shares, increasing direct ownership by 968% to 374,445 units (SEC Form 4)
- SEC Form 6-K filed by NovaBridge Biosciences
- SEC Form 6-K filed by NovaBridge Biosciences